The probiotic Bifidobacteria infantis: An assessment of potential antidepressant properties in the rat.

By L. Desbonnet, L. Garrett, G. Clarke, J. Bienenstock, Ted G. Dinan. Journal of Psychiatric Research, 2008

927 citations recorded by the source corpus.

Subfields: Biological Psychiatry, Molecular Biology, Pharmacy

View Paper: https://www.semanticscholar.org/paper/e516fe64f7bd0b1cea5b97bfa4fac0d7c904a39c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biological Psychiatry

1. J. Cryan
2. Ted G. Dinan
3. G. Clarke
4. P. Kennedy
5. C. Stanton
6. C. Nemeroff
7. Eléonore Beurel
8. M. Toups

In Molecular Biology

1. J. Cryan
2. Ted G. Dinan
3. G. Clarke
4. Patrice D Cani
5. C. Stanton
6. F. Bäckhed
7. P. Kennedy
8. N. Delzenne

In Pharmacy

1. J. Cryan
2. Ted G. Dinan
3. G. Clarke
4. C. Stanton
5. P. Kennedy
6. S. Grenham
7. R. Moloney
8. S. Mazmanian

Citations in the corpus

• Gut microbiota depletion from early adolescence in mice: Implications for brain and behaviour. (2015, methodology): “The monoamines noradrenaline (NA), serotonin (5-HT) and dopamine, and metabolites of these neurotransmitters including, 5-hydroxyindole acetic acid (5-HIAA), L-3,4-dihydroxyphenylalanine (L-DOPA), and dihydroxyphenylacetic acid (DOPAC) were measured in the frontal cortex, amygdala, and hippocampus b”
• Clinical and metabolic response to probiotic administration in patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial. (2016, background): “The administration of probiotics might result in improved symptoms of depression through increased plasma tryptophan levels, decreased serotonin metabolite concentrations in the frontal cortex, and decreased dopamine metabolite concentrations in the amygdaloid cortex [20].”
• Psychobiotics: a novel class of psychotropic. (2013, background): “infantis) increased levels of the serotonin precursor, tryptophan, in the plasma of rats, suggesting that the strain may have potential as an antidepressant (14).”
• Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity (2014, background): “Recent evidence also suggests that Bacteroides fragilis may prevent autism spectrum disorder in a mouse model (27) and that administration of probiotic Bifidobacterium infantis may have antidepressant properties in rats through changes in the tryptophan/kynurenine pathway (26).”
• Brain–Gut–Microbe Communication in Health and Disease (2011, methodology): “Monoassociation of GF animals with Bacteroides thetaiotaomicron, a representative strain of bacteria from the dominant microbial phyla, up-regulates sprr2a, a gene involved in desmosome maintenance and reinforcement of the intestinal barrier (Hooper et al., 2001).”
• Targeting the Microbiota-Gut-Brain Axis: Prebiotics Have Anxiolytic and Antidepressant-like Effects and Reverse the Impact of Chronic Stress in Mice. (2017, neutral): “Interestingly, multiple different alternative approaches to microbiota manipulation also demonstrate an impact on tryptophan availability, including germ-free animals (32), antibiotic-mediated depletion of the gut microbiota (6), and probiotic administration (38).”
• Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects (2010, neutral): “Lactobacillus and Bifidobacterium strains attenuated inflammatory responses or else induced IL-10 production in rodents (72–74) .”
• A randomized controlled trial to test the effect of multispecies probiotics on cognitive reactivity to sad mood. (2015, methodology): “For example, it has been proposed that intestinal microbiota increase plasma tryptophan levels, and hereby potentially facilitate serotonin turnover in the brain (Desbonnet et al., 2008, 2010).”